Both cladribine and alemtuzumab may effect MS via B-cell depletion
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received January 16, 2017
- Accepted in final form April 5, 2017
- First Published June 5, 2017.
Author Disclosures
- David Baker, PhD,
- Samuel S. Herrod, BSc,
- Cesar Alvarez-Gonzalez, PhD,
- Lukasz Zalewski, PhD,
- Christo Albor, PhD and
- Klaus Schmierer, PhD
- David Baker, PhD,
NONE
NONE
NONE
NONE
Patent filed via the university concerning the treatment of multiple sclerosis with cladribine and other compounds
NONE
NONE
Consultant for a Commercial entity (Canbex Therapeutics) that is unrelated to the subject of the manuscript
NONE
NONE
NONE
My laboratory received funds for research from a commercial entity (Genzyme Sanofi), unrelated to the subject of the manuscript in the past two years
NONE
The laboratory received funds for research from a academic entities unrelated to the subject of the manuscript
The laboratory received funds for research from Charities (Multiple sclerosis Society, Innovative UK/Technology Strategy Board, Diabetes UK, National Multiple Sclerosis Society), Fight for Sight for studies unrelated to the subject of the manuscript
I have recieved stock options from a commercial entity (Canbex Therapeutics) in the past to years or studies unrelated to the subject of the manuscript.
NONE
NONE
NONE
NONE
I provided consultancy to legal company acting on behalf of Teva, which was unrelated to the subject of the manuscript.
- Samuel S. Herrod, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The laboratory received funds for research from academic entities unrelated to the subject of the manuscript
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cesar Alvarez-Gonzalez, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The laboratory received funds for research from academic entities unrelated to the subject of the manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lukasz Zalewski, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christo Albor, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The laboratory received funds for research from academic entities unrelated to the subject of the manuscript.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Klaus Schmierer, PhD
(i) Novartis (ii) Biogen (iii) Merck Inc (iv) Teva (v) Merck Serono (vi) Roche
NONE
(i) Novartis, speaker honoraria (ii) Biogen, speaker honoraria (iii) Merck Inc, speaker honoraria (iv) Teva, speaker honoraria (v) Merck Serono, speaker honoraria (vi) Cinnagen, speaker honoraria (vii) Roche, speaker honoraria
MS Reports, editorial board, since Jun 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis
NONE
NONE
Barts Charity (468/1506) National MS Society (RG 4421A1/1; RG 4618A2/1) Royal College of Radiologists
NONE
NONE
NONE
NONE
NONE
NONE
- From the BartsMS (D.B., S.S.H., C.A.G., C.A., K.S.), Blizard Institute, ITS Research (L.Z.), Queen Mary University of London; and Barts Health NHS Trust (K.S.), Emergency Care & Acute Medicine Neuroscience Clinical Academic Group, London, UK.
- Correspondence to Dr. Schmierer: k.schmierer{at}qmul.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabHeinz Wiendl, Matthew Carraro, Giancarlo Comi et al.Neurology: Neuroimmunology & Neuroinflammation, October 29, 2019 -
Article
Mitigating alemtuzumab-associated autoimmunity in MSA “whack-a-mole” B-cell depletion strategyEthan Meltzer, Sarah Campbell, Benjamin Ehrenfeld et al.Neurology: Neuroimmunology & Neuroinflammation, August 07, 2020 -
Article
Alemtuzumab long-term immunologic effectTreg suppressor function increases up to 24 monthsStefania De Mercanti, Simona Rolla, Angele Cucci et al.Neurology - Neuroimmunology Neuroinflammation, January 21, 2016 -
Article
Monitoring B-cell repopulation after depletion therapy in neurologic patientsErik Ellwardt, Lea Ellwardt, Stefan Bittner et al.Neurology: Neuroimmunology & Neuroinflammation, April 25, 2018